PetVivo Holdings, Inc. (PETV)
Oxford Ledge is still expanding full research coverage of PETV. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
PetVivo develops and commercializes veterinary medical devices, primarily Spryng, for treating joint disease in companion animals using proprietary biomaterials.
Source: 10-K (2026-03-31) · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- 10-K Annual financial report with audited statements 2026-06-29
- 8-K Entry into material agreement; Regulation FD disclosure; Financial statements and exhibits 2026-06-25
- 8-K Entry into material agreement; 3.02; Financial statements and exhibits 2026-06-11
- 8-K Entry into material agreement; 3.02; Financial statements and exhibits 2026-04-17
- 8-K Entry into material agreement; 3.02; Financial statements and exhibits 2026-03-16
Source: SEC EDGAR.
Annual results
5 years of annual figures for PETV, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2026 | $1.1M | -$10.5M | -$0.38 |
| 2025 | $1.1M | -$8.4M | -$0.41 |
| 2024 | $968,706 | -$11.0M | -$0.78 |
| 2023 | $917,162 | -$8.7M | -$0.85 |
| 2022 | $115,586 | -$5.0M | — |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for PETV. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open PETV in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.